Career Enhancement Program

职业提升计划

基本信息

  • 批准号:
    10268748
  • 负责人:
  • 金额:
    $ 8.51万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-09-03 至 2026-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary – Career Enhancement Program The goal of the Career Enhancement Program (CEP) is to recruit, train and retain a diverse pool of outstanding early-career investigators who are committed to pursuing translational skin cancer research. The CEP will be led by two established investigators with complementary expertise in basic (Dr. Villanueva) and clinical (Dr. Schuchter) melanoma research. Both co-Directors are committed to training and mentoring of translational investigators and have an established record of recruiting and supporting women and minorities. The CEP will primarily assist junior faculty in their career development, but more established investigators interested in refocusing their research efforts on melanoma/skin cancer could also be considered. Women and underrepresented minorities will be strongly encouraged to participate. Likewise, projects aimed at addressing health disparities and/or skin cancer subtypes more common in underrepresented minorities will be encouraged and given special consideration. A team of clinicians, educators and researchers with broad expertise in translational research will ensure implementation of the specific aims of this program. With the support of the University of Pennsylvania, the Abramson Cancer Center and The Wistar Institute, the CEP will provide junior faculty the resources and guidance needed to establish innovative and fully funded independent skin cancer research programs and become future academic leaders. The CEP will provide awardees with two years of financial support for translational research projects in skin cancer with potential promotion to full SPORE projects or independent grant support. Awardees are required to actively participate in SPORE functions, use the SPORE Core resources, and provide both formal written progress reports and oral presentations. We have established high standards and expectations for the research mentors and a formalized program of long-term awardee mentorship. The program measures success by resulting publications, funding, and ultimately career advancement and national recognition. We have an outstanding talent pool of candidates and an effective training and mentorship program that will result in an exceptional group of skin cancer researchers. Our SPORE CEP has had an outstanding record recruiting and training investigators for careers in translational skin cancer research. Our past CEP awardees have published 74 papers during the past cycle and have been highly successful in obtaining peer reviewed funding from NCI and/or other funding agencies. In addition, all past awardees have transitioned from young investigators into leading academic positions and remain in the skin cancer field.
项目总结-职业提升计划

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jessie Villanueva其他文献

Jessie Villanueva的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jessie Villanueva', 18)}}的其他基金

Targeting S6K2 to Overcome Drug Resistance in NRAS-mutant Melanoma
靶向 S6K2 克服 NRAS 突变黑色素瘤的耐药性
  • 批准号:
    10539830
  • 财政年份:
    2022
  • 资助金额:
    $ 8.51万
  • 项目类别:
Career Enhancement Program
职业提升计划
  • 批准号:
    10480867
  • 财政年份:
    2021
  • 资助金额:
    $ 8.51万
  • 项目类别:
Targeting TERT in Melanoma
靶向黑色素瘤中的 TERT
  • 批准号:
    10247101
  • 财政年份:
    2017
  • 资助金额:
    $ 8.51万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10733193
  • 财政年份:
    2017
  • 资助金额:
    $ 8.51万
  • 项目类别:
Functional precision approaches to overcome intrinsic and acquired drug resistance in melanoma
克服黑色素瘤内在和获得性耐药性的功能精确方法
  • 批准号:
    10733196
  • 财政年份:
    2017
  • 资助金额:
    $ 8.51万
  • 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
  • 批准号:
    8634081
  • 财政年份:
    2013
  • 资助金额:
    $ 8.51万
  • 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
  • 批准号:
    9054086
  • 财政年份:
    2013
  • 资助金额:
    $ 8.51万
  • 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
  • 批准号:
    8826711
  • 财政年份:
    2013
  • 资助金额:
    $ 8.51万
  • 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
  • 批准号:
    9246446
  • 财政年份:
    2013
  • 资助金额:
    $ 8.51万
  • 项目类别:
Molecular approaches to overcome intrinsic drug resistance in BRAF and NRAS-mutan
克服 BRAF 和 NRAS-mutan 固有耐药性的分子方法
  • 批准号:
    8488046
  • 财政年份:
    2013
  • 资助金额:
    $ 8.51万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 8.51万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了